BerGenBio raises $15M for cancer R&D; Zafgen launches PhIIb; Ultragenyx begins pivotal PhIII;

@FierceBiotech: Novartis quarterbacks a $34M round for Huntington's startup Annexon. Report | Follow @FierceBiotech

@JohnCFierce: Who spends $295M upfront on a me-better Ph3 growth hormone? $PFE, that's who. Spending money like it's 1998. Release | Follow @JohnCFierce

@DamianFierce: $SNY and $REGN bought ahead of their expected PCSK9 launch. | Follow @DamianFierce

> Norway's BerGenBio AS, a biotech focused on new cancer drugs, has raised $15 million. That money is being earmarked for its lead drug candidate, BGB324, a selective Axl kinase inhibitor currently in Phase Ib for patients with acute myeloid leukemia. Release

> Boston-based Zafgen ($ZFGN) has launched a Phase IIb trial of its lead drug beloranib for obesity and Type 2 diabetes. Release

> Novato, CA-based Ultragenyx Pharmaceutical ($RARE) has dosed the first patient in the pivotal Phase III study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7. Release

Medical Device News

@FierceMedDev: ICYMI Friday: Strong one-year data for $BSX chronic pain implant, but reimbursement change stymies sales. Article | Follow @FierceMedDev

@StacyALawrence: How Long Can We Expect to Live? U.S. Life Expectancy Hits Record High. More | Follow @StacyALawrence

@EmilyWFierce: IRS battles it out with Medtronic and Covidien over offshore tax paying tactic. Story | Follow @EmilyWFierce

> FDA issues new guidance on MRI safety and compatibility of medical devices. More

> Spinal device maker LDR files to raise $150M. Article

Pharma News

@FiercePharma: Top-read pharma news this weekend: Actavis plan to stop making original Namenda derailed by court. Article | Follow @FiercePharma

@EricPFierce: ICMYI from FiercePharmaManufacturing: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. Piece | Follow @EricPFierce

@CarlyHFierce: The only thing that makes me happier on a Monday than a vaccines M&A story is one that involves the Czech Republic. Press release | Follow @CarlyHFierce

> Bayer fails last-ditch attempt to block India's cheap Nexavar copies. Story

> Stada, Dr. Reddy's and others dodge German drug suspensions with appeals. More

> Turnaround-minded Teva CEO scouts deals in specialty generics, emerging markets. Report

> Banks lost big betting on canceled AbbVie-Shire merger. Article

CRO News

> BioClinica snags a Pfizer exec to take the helm. Item

> CRO Health Decisions carries on after CEO's death. More

> Medidata burnishes its risk-based monitoring tech with latest buy. Report

> DaVita grows its in-house CRO with a data-centric merger. Story

> PPD's X-Chem pairs up with Alexion for drug discovery. Article

Biotech IT News

> Autism Speaks to make Google-underpinned genomics database freely available. More

> Early Medidata backer plans $150M digital-health fund. Article

> Pfizer turns to app to overcome rare disease enrollment bottleneck. Item

> Flatiron maintains dealmaking pace with patient-reported outcome data hookup. Story

> Transcriptic offers Y Combinator biotechs $20,000 credit for its robotic labs. Report

Animal Health News

> Parnell shakes up management team, woos investors, as shares stagnate. News

> Kansas State researchers model U.S. outbreak of foot-and-mouth. Report

> European and U.S. scientists warn veterinary meds are endangering wildlife. More

> Will the $8.2B buyout of PetSmart affect its in-store Banfield pet hospitals? Story

> Sanofi chairman hints at animal health deals, sending Zoetis shares soaring. Article

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.